OUR 9TH YEAR OF PROVIDING PROPRIETARY CAPITAL MARKETS INTELLIGENCE ON THE CANNABIS / HEMP / PSYCHEDELIC SECTORS
Quick
Links
More Charts
Credit Tracker By Industry Sector
Credit Tracker By Sector
Credit ratings are not currently available for public cannabis companies leaving companies, lenders and investors with a gap of information. The Viridian Cannabis Credit Tracker fills this gap. The model uses 11 market and financial statement variables to discern 4 key credit factors: Liquidity, Leverage, Profitability, and Size, to provide credit/liquidity analysis for over 370 public Cannabis/Hemp companies.
Week ended 09/08/2023
The credit quality of the Biotech/Pharma sector has generally improved over the last several weeks: the median free cash flow adjusted current ratio is still very weak at .04x, but it is up from a negative reading several weeks earlier. Similarly, total liabilities to market cap is down from .45x on 8/25 to .35x. Despite this recent improvement, we see a weaker picture than last year, with a deterioration in liquidity and leverage stats.
Week ended 09/08/2023
The credit quality of the Biotech/Pharma sector has generally improved over the last several weeks: the median free cash flow adjusted current ratio is still very weak at .04x, but it is up from a negative reading several weeks earlier. Similarly, total liabilities to market cap is down from .45x on 8/25 to .35x. Despite this recent improvement, we see a weaker picture than last year, with a deterioration in liquidity and leverage stats.
This Chart is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
